Accord Biopharma, Inc.
Raleigh, NC Part of Accord Healthcare, Inc.
- UEI
- M3PMHL5VML74
- CAGE
- 98XD1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
Raleigh, NC
KC4PVKBH1LD7
-
Parent
Raleigh, NC
KC4PVKBH1LD7
- SAM.gov registration date
- Physical address
- 8041 Arco Corporate Dr #200, Raleigh, NC 27617, USA
- Website
- accordbiopharma.com
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $7,615,500 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $7,615,500 |
Contract vehicles
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pegfilgrastim 6MG/.06ML (INJ, soln, SYR or autoinjector) and VMI | Office of the Assistant Secretary for Preparedness and Response | $19,420,700 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Genentech Usa, Inc. | South San Francisco, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Arrowhead Pharmaceuticals, Inc. | Pasadena, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Incyte Corporation | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
| Fagron Sterile Services | Wichita, KS | 325412 Pharmaceutical Preparation Manufacturing |
| Servier Pharmaceuticals LLC | Boston, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Accord Biopharma, Inc., a foreign-owned subsidiary of Accord Healthcare, Inc., operates as a pharmaceutical manufacturer and supplier providing pegfilgrastim products and vendor-managed inventory services to federal healthcare customers as a prime contractor under full-and-open procurements with no set-aside designations.
Accord Biopharma competes exclusively in the pharmaceutical supply space, classified under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC code for Drugs and Biologicals. All four prime awards in the source portfolio target the same product line: pegfilgrastim 6mg/.06ml in injection, solution, syringe, and autoinjector formats. The company's federal footprint centers on three customer agencies. The Department of Health and Human Services, Administration for Strategic Preparedness and Response (through the Center for the Strategic National Stockpile) awarded a definitive firm fixed-price contract on March 19, 2025, for pegfilgrastim procurement and VMI services with a ceiling value of $45.2 million and an ultimate completion date of March 18, 2030; the contract covers up to 60,300 units across a base period and four optional twelve-month ordering periods, with performance in Redwood City, California. The Department of Veterans Affairs National Acquisition Center awarded a single-award indefinite-delivery contract on April 11, 2025, valued at $27.6 million, running through April 10, 2030, for pegfilgrastim supply to the VA (including Consolidated Mail Order Pharmacies and State Veterans Homes), the Bureau of Prisons, the Indian Health Service, and Federal Health Care Centers, with estimated annual usage of 8,458 units. Accord Biopharma also holds GSA Federal Supply Schedule positions under the Pharmaceuticals and Drugs schedule (FSS-61-IB) for Special Item Number 65 I B, Drugs, Pharmaceuticals & Hematology Related Products, with a current $300,000 ceiling and December 14, 2027 expiration.
Combined potential value across all awards stands at $73.1 million, with $45.2 million (62%) anchored to the SNS contract and $27.6 million (38%) to the VA National Acquisition Center IDC. Obligations total $19.4 million (27% of potential value). The vendor holds no subcontract positions in the source data; all four awards are prime positions. Accord Biopharma's parent, Accord Healthcare, Inc., also holds federal contract vehicles but has not awarded separate prime contracts in the source portfolio.
Quick answers
Is Accord Biopharma, Inc. registered in SAM.gov?
Yes. Accord Biopharma, Inc.'s SAM.gov registration is active through July 23, 2027.
What is Accord Biopharma, Inc.'s CAGE code?
Accord Biopharma, Inc.'s CAGE code is 98XD1, and its Unique Entity ID (UEI) is M3PMHL5VML74.
Which contract vehicles does Accord Biopharma, Inc. hold?
Accord Biopharma, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Accord Biopharma, Inc. received in federal contracts?
Federal contracts obligated $7,615,500 to Accord Biopharma, Inc. in fiscal years 2023 through 2027.
What is Accord Biopharma, Inc.'s most recent federal award?
Accord Biopharma, Inc.'s most recent federal contract award is Pegfilgrastim 6MG/.06ML (INJ, soln, SYR or autoinjector) and VMI (75A50325C00002), from Office of the Assistant Secretary for Preparedness and Response, on March 19, 2025.
On GovTribe
See Accord Biopharma, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors